[HTML][HTML] Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: a phase 1 open-label clinical trial in healthy adults
Background VRC01 is a human broadly neutralizing monoclonal antibody (bnMAb) against
the CD4-binding site of the HIV-1 envelope glycoprotein (Env) that is currently being …
the CD4-binding site of the HIV-1 envelope glycoprotein (Env) that is currently being …
Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: a Phase 1 open-label clinical trial in healthy adults.
MR Gaudinski, EE Coates, KV Houser, GL Chen… - 2018 - cabidigitallibrary.org
Background: VRC01 is a human broadly neutralizing monoclonal antibody (bnMAb) against
the CD4-binding site of the HIV-1 envelope glycoprotein (Env) that is currently being …
the CD4-binding site of the HIV-1 envelope glycoprotein (Env) that is currently being …
Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults
MR Gaudinski, EE Coates, KV Houser, GL Chen… - PLOS …, 2018 - ideas.repec.org
Background: VRC01 is a human broadly neutralizing monoclonal antibody (bnMAb) against
the CD4-binding site of the HIV-1 envelope glycoprotein (Env) that is currently being …
the CD4-binding site of the HIV-1 envelope glycoprotein (Env) that is currently being …
Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults.
MR Gaudinski, EE Coates, KV Houser, GL Chen… - Plos …, 2018 - europepmc.org
Background VRC01 is a human broadly neutralizing monoclonal antibody (bnMAb) against
the CD4-binding site of the HIV-1 envelope glycoprotein (Env) that is currently being …
the CD4-binding site of the HIV-1 envelope glycoprotein (Env) that is currently being …
Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults
MR Gaudinski, EE Coates, KV Houser… - PLoS …, 2018 - pubmed.ncbi.nlm.nih.gov
Background VRC01 is a human broadly neutralizing monoclonal antibody (bnMAb) against
the CD4-binding site of the HIV-1 envelope glycoprotein (Env) that is currently being …
the CD4-binding site of the HIV-1 envelope glycoprotein (Env) that is currently being …
[引用][C] Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults
MR Gaudinski, EE Coates, KV Houser, GL Chen… - PLOS Medicine, 2018 - cir.nii.ac.jp
Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS:
A Phase 1 open-label clinical trial in healthy adults | CiNii Research CiNii 国立情報学研究所 …
A Phase 1 open-label clinical trial in healthy adults | CiNii Research CiNii 国立情報学研究所 …
Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults
MR Gaudinski, EE Coates, KV Houser… - PLoS …, 2018 - search.proquest.com
Background VRC01 is a human broadly neutralizing monoclonal antibody (bnMAb) against
the CD4-binding site of the HIV-1 envelope glycoprotein (Env) that is currently being …
the CD4-binding site of the HIV-1 envelope glycoprotein (Env) that is currently being …
[PDF][PDF] Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults
MR Gaudinski, EE Coates, KV Houser… - PLoS …, 2018 - pdfs.semanticscholar.org
Background VRC01 is a human broadly neutralizing monoclonal antibody (bnMAb) against
the CD4-binding site of the HIV-1 envelope glycoprotein (Env) that is currently being …
the CD4-binding site of the HIV-1 envelope glycoprotein (Env) that is currently being …
[HTML][HTML] Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults
MR Gaudinski, EE Coates, KV Houser, GL Chen… - PLoS …, 2018 - ncbi.nlm.nih.gov
Background VRC01 is a human broadly neutralizing monoclonal antibody (bnMAb) against
the CD4-binding site of the HIV-1 envelope glycoprotein (Env) that is currently being …
the CD4-binding site of the HIV-1 envelope glycoprotein (Env) that is currently being …
Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults.
MR Gaudinski, EE Coates, KV Houser, GL Chen… - PLoS Medicine, 2018 - go.gale.com
Background VRC01 is a human broadly neutralizing monoclonal antibody (bnMAb) against
the CD4-binding site of the HIV-1 envelope glycoprotein (Env) that is currently being …
the CD4-binding site of the HIV-1 envelope glycoprotein (Env) that is currently being …